Cell and Gene Therapy

With a foundation built on decades of research and collaboration with leading investigators, our Cell and Gene Therapy team brings more than 45 years of invaluable expertise in conducting clinical trials to our customers.

Our innovations are unlocking real research potential to test and create life-changing treatments for patients suffering from a wide range of conditions and diseases.

Why Emmes?

Proven Expertise

Our 125+ clinical studies are focused on advancing cell or gene therapies in therapeutic areas including hematology/oncology, ophthalmology, cardiology, and pulmonology.
71 total submissions to regulatory agencies since 2019, including 15 IND/CTA submissions.
Over 100 scientific manuscripts co-authored by Emmes staff that include cell and gene therapy research results and progress.

Emmes Solutions and Services

Our comprehensive services include clinical trial operations,
study leadership, statistical services, and pharmacovigilance,
along with regulatory, training and educational support.

With a depth and breadth of credentials and experience at all
levels, we can help you to maximize site and patient-level data
with electronic data capture of CRFs, patient reported outcomes
and diaries, and data from phone apps, wearables, and other
digital technologies.

A valuable partner and collaborator with influential members of the cell and gene scientific community.

“We selected Emmes to provide these services because of their outstanding reputation and high quality of their work. Given the novelty of the study, it was critical to have the best organization evaluating and interpreting the data.”

Dr. Joanne Kurtzberg, M.D.
Senior Author and Director, Duke University Medical Center

Complex Clinical Trials

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

The BMT CTN is one of our longest-running, most collaborative and complex research partnerships. The BMT CTN sets out to evaluate promising therapeutic approaches in multi-institutional clinical trials, aiming to improve the outcomes of blood and marrow transplantation and other cellular therapies for patients facing life-threatening blood disorders. The BMT CTN leverages processes and data from the Center for International Blood and Marrow Transplant Research (CIBMTR) that allows the BMT CTN to design and conduct these complex studies effectively.

It’s funded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute, in collaboration with biopharma companies. Other partners are the National Marrow Donor Program/Be the Match (NMDP) and the Medical College of Wisconsin (MCW).

Established in 2001, our partnership with NMDP MCW is the foundation of a program led by experts in the field of hematopoietic cell transplantation and cellular therapy.

In sharing responsibility, Emmes manages study operations, NMDP looks after patient advocacy and contracting, and MCW takes care of scientific leadership.